王莲凤 周倩

【摘要】目的：观察伐昔洛韦抗病毒抑制疗法治疗频发性生殖器疱疹的临床效果及预后效果。方法：从2012年8月至2014年8月我院收治的频发性生殖器疱疹中选取108例作为研究对象，按随机分组法分为A组和B组，各54例。A组采用持续抑制疗法，B组采用间歇疗法。分别于用药期间观察两组复发情况及不良反应。结果：A组在治疗期间与治疗后随访期间的复发率20.37%、48.15%，均低于B组的87.04%、92.59%；两组治疗后随访1年的复发次数均明显减少，且A组复发次数为（0.9±0.7）次，低于B组的（2.4±1.1）次。上述差异均有统计学意义（P<0.05）。两组的不良反应发生率比较，差异无统计学意义（P>0.05）。结论：伐昔洛韦抗病毒抑制疗法治疗频发性生殖器疱疹临床疗效显著，预后良好，值得临床推荐。

【关键词】伐昔洛韦；病毒抑制疗法；频发性生殖器疱疹；效果

【Abstract】Objectives： To observe the effect of valaciclovir suppressive antiviral therapy in the treatment of frequent clinical effect and prognosis of recurrent genital herpes. Methods： From August 2012 to August 2014， 108 patients with recurrent genital herpes were selected and randomly divided into group A and group B. The group A was inhibited by continuous treatment， and group B was intermittent therapy. Two groups were observed during the treatment and adverse reactions were observed. Results： The recurrence rate of group A during and after treatment was 20.37% and 48.15%， which was lower than that of B group of 92.59% and 87.04%. In the 1 year follow-up， the number of recurrence of group A was （0.9 ± 0.7）， lower than the group B （2.4 ± 1.1）. The difference was statistically significant （P < 0.05）. Difference in the incidence of adverse reactions in the two groups was not statistically significant （P > 0.05）. Conclusion： Valacyclovir antiviral suppression therapy in the treatment of frequent sexual genital bleb has a significant clinical efficacy with good prognosis， worthy of clinical recommendations.

【Key words】Valaciclovir； Viral suppression therapy； Recurrent genital herpes； Effect

【中图分类号】R752.1【文献标志码】A

生殖器疱疹（genital herpes，GH）是由单纯疱疹病毒感染而引起的一种常见的性传播疾病[1]。据WHO统计，生殖器疱疹的发病率呈逐年上升的趋势[2]。由于该病具有治愈难、传播性强且反复发作等特点，可以通过性、母婴传播，因而严重影响患者及其家庭的生活质量。伐昔洛韦是治疗频发性生殖器疱疹的首选药物，在2009年之前，其剂量多以300mg为主。而大量研究显示，应用500mg伐昔洛韦抑制疗法对生殖器疱疹进行治疗，其临床疗效确定，不良反应少[3，4]。为此，本文应用伐昔洛韦间歇疗效和持续抑制疗法对频发性生殖器疱疹患者进行治疗，旨在探究大剂量持续抑制疗法治疗频发性生殖器疱疹的临床疗效及预后效果。现报道如下。……